Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 13.

Hachfeld, A; Darling, K; Calmy, A; Ledergerber, B; Weber, R; Battegay, M; Wissel, K; Di Benedetto, C; Fux, C A; Tarr, P E; Kouyos, R; Ruggia, L S; Furrer, H J; Wandeler, G; Swiss HIV Cohort Study (2019). Why do sub-Saharan Africans present late for HIV care in Switzerland? HIV Medicine, 20(6):418-423.

Young, J; Wang, Q; Fux, C A; Bernasconi, E; Furrer, H; Vernazza, P; Calmy, A; Cavassini, M; Weber, R; Battegay, M; Bucher, H C (2014). The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. HIV Medicine, 15(8):505-510.

Cusini, A; Vernazza, P L; Yerly, S; Decosterd, L A; Ledergerber, B; Fux, C A; Rohrbach, J; Widmer, N; Hirschel, B; Gaudenz, R; Cavassini, M; Klimkait, Th; Zenger, F; Gutmann, C; Opravil, M; Günthard, H F (2013). Higher CNS Penetration-Effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. Journal of Acquired Immune Deficiency Syndromes, 62(1):28-35.

Fux, C A; Baumann, S; Furrer, H; Mueller, N J (2011). Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class? AIDS, 25(6):876-878.

Fehr, J; Glass, T R; Louvel, S; Hamy, F; Hirsch, H H; von Wyl, V; Böni, J; Yerly, S; Bürgisser, P; Cavassini, M; Fux, C A; Hirschel, B; Vernazza, P; Martinetti, G; Bernasconi, E; Günthard, H F; Battegay, M; Bucher, H C; Klimkait, T (2011). Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study. Journal of Translational Medicine, 9:14.

Opravil, M; Klimkait, T; Louvel, S; Wolf, E; Battegay, M; Fux, C A; Bernasconi, E; Vogel, M; Speck, R; Weber, R (2010). Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(1):51-58.

Scherrer, A U; von Wyl, V; Fux, C A; Opravil, M; Bucher, H C; Fayet, A; Decosterd, L A; Hirschel, B; Khanlari, B; Yerly, S; Klimkait, T; Furrer, H; Ledergerber, B; Günthard, H F (2010). Implementation of Raltegravir in routine clinical practice: Selection criteria for choosing this drug, virologic response rates, and characteristics of failures. JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(4):464-471.

Mueller, N J; Fux, C A; Ledergerber, B; Elzi, L; Schmid, P; Dang, T; Magenta, L; Calmy, A; Vergopoulos, A; Bischoff-Ferrari, H A (2010). High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS, 24(8):1127-1134.

Elzi, L; Kaufmann, G; Weber, R; Fux, C A; Cavassini, M; Hirschel, B; Vernazza, P; Bernasconi, E; Battegay, M (2009). Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. HIV Clinical Trials, 10(4):207-214.

Khanna, N; Elzi, L; Mueller, N J; Garzoni, C; Cavassini, M; Fux, C A; Vernazza, P; Bernasconi, E; Battegay, M; Hirsch, H H (2009). Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clinical Infectious Diseases, 48(10):1459-1466.

Khanna, N; Wolbers, M; Mueller, N J; Garzoni, C; Du Pasquier, R A; Fux, C A; Vernazza, P; Bernasconi, E; Viscidi, R; Battegay, M; Hirsch, H H (2009). JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. Journal of Virology, 83(9):4404-4411.

Young, J; Bucher, H C; Guenthard, H F; Rickenbach, M; Fux, C A; Hirschel, B; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M (2009). Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. Antiviral Therapy, 14(6):771-779.

Wunder, D M; Fux, C A; Bersinger, N A; Mueller, N J; Hirschel, B; Cavassini, M; Elzi, L; Schmid, P; Bernasconi, E; Mueller, B; Furrer, H (2008). Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study. HIV Medicine, 9(6):427-432.

This list was generated on Mon Sep 23 13:20:25 2019 CEST.